Vanguard Capital Management
NAGE

Vanguard Capital Management’s Niagen Bioscience NAGE Stock Holding History

Vanguard Capital Management’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.85M Sell
2,147,018
-2,259
-0.1% -$9.17K ﹤0.01% 2999
2026
Q1 		$9.48M Buy
+2,149,277
New +$11.6M ﹤0.01% 2759

Other funds holding NAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management's NAGE Position: Q2 2026 in Review

Vanguard Capital Management reduced its Niagen Bioscience (NAGE) stake by 0.11% in Q2 2026, selling an estimated $9.17K and leaving 2,147,018 shares worth $6.85M. The position accounts for ﹤0.01% of the portfolio, ranked #2999.

Vanguard Capital Management first reported a position in NAGE in Q1 2026 and has held it in 2 quarters since. The position peaked at $9.48M in Q1 2026. 139 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

  • Vanguard Capital Management held 2,147,018 shares of Niagen Bioscience worth $6.85M as of Q2 2026.
  • Vanguard Capital Management sold 2,259 Niagen Bioscience shares in Q2 2026, an estimated $9.17K.
  • Niagen Bioscience made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2999 holding.
  • Vanguard Capital Management first reported a position in Niagen Bioscience in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Niagen Bioscience position peaked at $9.48M in Q1 2026.
  • 139 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.